Kristin Brooks01.08.14
Amar Singh has been appointed executive vice president and chief business officer at Sorrento Therapeutics. Mr. Singh will be responsible for overseeing partnering activities. He has more than 25 years of experience in business and commercial development, strategic planning and operations.
Mr. Singh joins the company from Synta Pharmaceuticals, where he served as senior vice president and chief business officer, responsible for leading business and commercial development, clinical operations, project management, CMC, and quality assurance. Prior to Synta, Mr. Singh was chief operating officer at Spectrum Pharmaceuticals, where he spearheaded numerous strategic and commercial transactions, including the in-licensing of Belinostat. Mr. Singh also served as vice president and chief commercial officer at Novacea, led the launch of the proprietary division of American Pharmaceutical Partners – Abraxis Oncology, and held several leadership positions in the oncology franchise at Hoffmann-La Roche.
"Amar joins us at a pivotal phase in our company's growth as we advance Cynviloq into its registrational trial and continue the development of resiniferatoxin (RTX)," said Henry Ji, Ph.D., president and chief executive officer of Sorrento. "His successful track record of initiating and closing complex transactions, in addition to managing strategic alliances, will be particularly useful for both our clinical as well as early-stage programs."
Mr. Singh joins the company from Synta Pharmaceuticals, where he served as senior vice president and chief business officer, responsible for leading business and commercial development, clinical operations, project management, CMC, and quality assurance. Prior to Synta, Mr. Singh was chief operating officer at Spectrum Pharmaceuticals, where he spearheaded numerous strategic and commercial transactions, including the in-licensing of Belinostat. Mr. Singh also served as vice president and chief commercial officer at Novacea, led the launch of the proprietary division of American Pharmaceutical Partners – Abraxis Oncology, and held several leadership positions in the oncology franchise at Hoffmann-La Roche.
"Amar joins us at a pivotal phase in our company's growth as we advance Cynviloq into its registrational trial and continue the development of resiniferatoxin (RTX)," said Henry Ji, Ph.D., president and chief executive officer of Sorrento. "His successful track record of initiating and closing complex transactions, in addition to managing strategic alliances, will be particularly useful for both our clinical as well as early-stage programs."
